Merus NV Stock News

UTRECHT, The Netherlands and CAMBRIDGE, Mass., Dec. 06, 2021 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today released clinical data on MCLA-145 from the phase 1 trial in patients with solid tumors at the ESMO Immuno-Oncology Congress 2021 being held virtually.

The omicron variant concerns were front and center in the markets in the week ended Dec. 3, and biotech stocks did not escape the brunt of selling in the wake of the negative development. The sector r

UTRECHT, Pays-Bas et CAMBRIDGE, Massachusetts, 03 déc. 2021 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq : MRUS) (« Merus », la « Société », « nous », ou « notre/nos »), une société

UTRECHT, Niederlande und CAMBRIDGE, Mass., Dec. 03, 2021 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) („Merus“, „das Unternehmen“, „wir“ oder „unser“), ein Unternehmen aus dem Berei

UTRECHT, The Netherlands and CAMBRIDGE, Mass., Dec. 02, 2021 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) ("Merus", "the Company", "we", or "our"), a clinical-stage oncology company developing inn

UTRECHT, The Netherlands and CAMBRIDGE, Mass., Dec. 02, 2021 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ: MRUS ) ("Merus", "the Company", "we", or "our"), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics ® and Triclonics ® ), today announced the publication of the abstract highlighting interim data, as of a July 14, 2021 cutoff, from the phase 1/2 trial of bispecific antibody MCLA-145 in patients with solid tumors. The e-poster will be presented at the ESMO Immuno-Oncology (ESMO IO) Congress 2021 being held December 8-11, 2021 in Geneva, Switzerland. Presentation Details: Title: Phase I Dose Escalation Study of MCLA-145, a Bispecific Antibody Targeting CD137 and PD-L1 in Solid Tumors Poster #: 136P The e-poster will be available on the virtual platform, in the e-poster section as of Monday, December 6 at 6:00 am ET and on-site at the e-Poster stations starting on Wednesday, December 8. The poster will also be available on the Merus website .

Related Stocks: AMRN , KYMR , LXRX , CRNX , RAIN , VSTM , GLPG , AADI , TYRA , PNT , ALPN , ELEV , MRUS , RACA , FBRX , IMVT , CNTA ,

Related Stocks: ISEE , ACRS , VRDN , KURA , PTGX , VTGN , DRNA , MRUS , TNYA , IOVA , RVMD , CNST , MGNX , EPIX , MRSN , MCRB ,

Merus N.V. (MRUS) delivered earnings and revenue surprises of 40.91% and 29.84%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Merus N.V. (MRUS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Merus N.V. (MRUS) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase

The stock price Merus NV (NASDAQ: MRUS) increased by over 35% today. This is why it happened.

This biotech's second experimental cancer drug to begin clinical trials produced some encouraging results.

UTRECHT, The Netherlands and CAMBRIDGE, Mass., Oct. 07, 2021 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “the Company”, “we”, or “our”), a clinical-stage oncology company d

UTRECHT, The Netherlands and CAMBRIDGE, Mass., Sept. 30, 2021 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “the Company”, “we”, or “our”), a clinical-stage oncology company